1-3 of 3
Paul Mainwaring, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors

Andrew Spencer, Simon Harrison, MD, Francis Burrows, Paul Mainwaring, MD, Timothy Price, MD, Michael J Millward, MD, Peeter Padrik, MD, Craig Underhill, MD, Paul Cannell, MD, Steven D Reich, MD, Mohit Trikha, PhD
Journal: Blood
Blood (2015) 126 (23): 5375.
https://doi.org/10.1182/blood.V126.23.5375.5375
Published: 2015
Journal Articles

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052.

Andrew Spencer, Michael Millward, MD, Paul Mainwaring, MD, Simon Harrison, MD, Laurence Catley, MBBS, FRCPA, FRACP, Amanda Townsend, MD, Shawgi Sukumaran, MD, Angie M. Longenecker, RN, BSN, Michael A. Palladino, PhD, G. Kenneth Lloyd, PhD, Saskia Neuteboom, PhD, Peeter Padrik, MD, Matthew A. Spear, MD, Timothy Price, MD
Journal: Blood
Blood (2009) 114 (22): 2693.
https://doi.org/10.1182/blood.V114.22.2693.2693
Published: 2009
Journal Articles

Clinical Trial of NPI-0052 (2nd generation proteasome inhibitor) in Patients Having Advanced Malignancies with Expanded RP2D Cohorts in Lymphoma and CLL

Timothy Price, MD, Peeter Padrik, MD, Amanda Townsend, MD, Paul Mainwaring, MD, Lawrence Catley, MD, Angie M. Longenecker, RN, BSN, Gillian Cropp, MS, Michael A. Palladino, PhD, G. Kenneth Lloyd, PhD, Matthew A. Spear, MD, Michael Millward, MD
Journal: Blood
Blood (2008) 112 (11): 4934.
https://doi.org/10.1182/blood.V112.11.4934.4934
Published: 2008